Glenmark Pharmaceuticals share price
You have to be logged in to add this to Watchlist.- ₹1,509.90(2.15%)March 21, 2025 15:29:29 PM IST
- NSE
- BSE
- Vol : 857.41K (NSE + BSE)Last 20 day avg : 517.67 K
Glenmark Pharmaceuticals is trading 2.15% upper at Rs 1,509.90 as compared to its last closing price. Glenmark Pharmaceuticals has been trading in the price range of 1,517.95 & 1,487.95. Glenmark Pharmaceuticals has given -8.10% in this year & 3.97% in the last 5 days. There are 9 analysts who have initiated coverage on Glenmark Pharmaceuticals. There are 4 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.The company posted a net profit of 347.96 Crores in its last quarter.Listed peers of Glenmark Pharmaceuticals include Alkem Laboratories (2.01%), Glaxosmithkline Pharmaceutical (2.90%), Glenmark Pharmaceuticals (2.15%).The Mutual Fund holding in Glenmark Pharmaceuticals was at 12.12% in 31 Dec 2024. The MF holding has increased from the last quarter. The FII holding in Glenmark Pharmaceuticals was at 23.51% in 31 Dec 2024. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Mar 21, 2025, 05:42 PM UTC
- Dividend YieldLower than industry0.17Annual dividends as a percentage of the stock price.
- P/BHigher than historical values5.32The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values0.00Price-to-earnings ratio based on trailing 12-month earnings
- BetaMedium volatility1.11Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.16The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in December quarter by 35.14% from Rs 3387.55 crore to Rs 2506.70 crore, year-on-year
- Company has registered a profit of 347.96 cr vs a loss of 351.37 cr in the same quarter last year.
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 1,428.50
- R2
- 1,578.25
- R3
- 1,655.15
- S1
- 1,201.85
- S2
- 1,124.95
- S3
- 975.20
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Alkem Laboratories | Neutral | 5,000.95 | 2.01 | 59,540.25 | 32.25 | 5.63 | 0.87 | 2.22 |
| Glaxosmithkline Pharmaceutical | Bullish | 2,943.60 | 2.90 | 49,866.36 | 69.37 | 27.05 | 1.13 | 0.36 |
| Glenmark Pharmaceuticals | Bullish | 1,509.90 | 2.15 | 42,607.59 | - | 5.35 | 0.17 | 1.93 |
| Biocon | Neutral | 343.95 | 0.87 | 41,294.63 | 43.36 | 2.07 | 0.15 | 67.86 |
| Ipca Laboratories | Neutral | 1,412.20 | 0.83 | 35,821.47 | 52.58 | 5.45 | 0.29 | 9.80 |
- Promoter(s) holding is moderate at 46.65%
- Promoter(s) have increased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has increased by 0.46 percentage points from previous quarter
- Mutual Funds holding has increased by 0.71 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-02-14 | Quarterly Results |
| 2024-11-14 | Quarterly Results |
| 2024-08-14 | Quarterly Results |
| 2024-05-24 | Audited Results & Final Dividend |
| 2024-02-14 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE935A01035
- BSE Code532296
- NSE CodeGLENMARK
Glenmark Pharmaceuticals is trading at 1509.90 as on Fri Mar 21 2025 09:59:29. This is 2.15% upper as compared to its previous closing price of 1478.15.
The market capitalization of Glenmark Pharmaceuticals is 42607.59 Cr as on Fri Mar 21 2025 09:59:29.
The average broker rating on Glenmark Pharmaceuticals is Buy. The breakup of analyst rating is given below -
- 4 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 3 analysts have given a hold rating
- 1 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Glenmark Pharmaceuticals is 1830.05 whereas the 52 wk low is 908.90
Glenmark Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: 30.97
- Dividend Yield: 0.17%
- D/E ratio: -
Glenmark Pharmaceuticals reported a net profit of -1501.67 Cr in 2024.
The Mutual Fund Shareholding was 12.12% at the end of 31 Dec 2024.